Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
European Commission · Horizon Europe Framework Programme (HORIZON)
Publicada 10 feb 2027 · Quedan aproximadamente 11 meses
En pocas palabras
Resumen aún no disponible en español; se muestra en inglés.
The European Commission funds clinical research programmes by comprehensive cancer centres to improve diagnosis and treatment of lung, bowel, breast and prostate cancer for patients across Europe. Grants range from 3 to 10 million euros, applications open 10 February 2027 and are due by 21 September 2027, submitted in English through the portal.
Un resumen generado del texto del donante; la redacción original figura más abajo.
Resumen
Texto original del donante (inglés)
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
Patients afflicted by lung, bowel, breast or prostate cancer[1], will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures[2].
Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators[3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.
National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or…
Extracto de la página del donante. El texto completo, los anexos y los formularios están en la convocatoria original.
Regiones elegibles
- Estados miembros de la UE
Quién puede presentar una solicitud
- ONG / sociedad civil
- Institución académica o de investigación
- Empresa privada
- Organismo gubernamental
- Agencia de la ONU u organismo intergubernamental
Elegibilidad y condiciones
Mostrar el texto de elegibilidad de la fuente · Texto original del donante (inglés)
General conditions
1. Admissibility conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
described in Annex G of the Work Programme General Annexes.
Specific conditions
described in the specific topic of the Work Programme
Application and evaluation forms and model grant agreement (MGA):
Application form templates
Please use the application form that you will find in the Submission System. You can find examples of standard application forms in the Reference Documents page.
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA)
Guidance
HE Programme Guide
Model Grant Agreements (MGA)
Lump Sum MGA
Call-specific instructions
Detailed budget table (HE LS)
Information on clinical studies (HE)
Guidance: "Lump sums - what do I need to know?"
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 12. Missions
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Framework Programme and Rules for Participation Regulation 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement